New 6-month findings from the RELIEVE-PN study suggest individuals with prurigo nodularis treated with dupilumab (Dupixent) show significant improvements in their levels of itch and nodule clearance.

These new results were highlighted during an 

American Academy of Dermatology (AAD) Annual Meeting

, with trial investigator Sarina Elmariah, MD, PhD, MPH, professor of dermatology at the University of California, San Francisco School of Medicine. Elmariah responded to several questions regarding the RELIEVE-PN study, the results’ significance for prurigo nodularis, and more.

Prurigo nodularis is a serious, chronic inflammatory skin condition known for its persistent itch and isolated pruritic firm papules and nodules.

 The following Q&A summary highlights Elmariah’s responses to 

’s inquiries regarding dupilumab for prurigo nodularis:

 Can you start by giving an overview of the RELIEVE-PN study and what question you were aiming to answer with this analysis?

This is an ongoing, real-world study to evaluate Dupixent in clinical practice for adults with prurigo nodularis using patient-reported surveys. This specific analysis assessed interim outcomes related to itch and nodule clearance after 6 months of Dupixent treatment.

How was the study designed, and what makes this real-world, longitudinal survey approach important for understanding outcomes in patients with prurigo nodularis?

 Adults with prurigo nodularis enrolled in the U.S. Dupixent patient support program were recruited for the study. Patients received surveys at baseline and then at 1, 3 and 6 months following Dupixent initiation. Real-world evidence studies like this provide important additional insights into the impact Dupixent can have in clinical practice and further support its approved use for the treatment of adults with prurigo nodularis.

What were the key findings at the 6-month mark, particularly in terms of itch reduction and nodule clearance?

After 6 months of treatment with Dupixent, a significantly higher proportion of patients had ≤5 nodules and no-to-mild itch compared to baseline, which was consistent across the overall population as well as those who continued Dupixent through 6 months (the majority of patients stayed on Dupixent at 1, 3 and 6 months post Dupixent initiation). These significant reductions in nodules and itch started as early as 1 month after patients started taking Dupixent.

How do you interpret the clinical significance of these improvements for patients living with prurigo nodularis?

These results reinforce the efficacy we’ve already seen with Dupixent, but, importantly, demonstrate, in real-world clinical practice, patients themselves are reporting significant reductions in two key outcomes that are particularly burdensome: itch and nodules.

Looking ahead, how do you see these data influencing clinical practice or shaping future research on dupilumab and PN?

 Dupixent is already approved for the treatment of adults with prurigo nodularis, but these results further support its established efficacy in these patients and demonstrate that patients are feeling the improvements themselves in real-world clinical practice.

The quotes used in this Q&A interview summary were edited for clarity.

Elmariah has served as an advisory board member, consultant, investigator, and/or speaker for Bellus Health, Celldex Therapeutics, Eli Lilly, Galderma, Incyte, New Frontier Bio, Pfizer, Regeneron Pharmaceuticals Inc., Sanofi, and Trevi Therapeutics.

Elmariah S, et al. Patients with prurigo nodularis treated with dupilumab experience significant improvement in itch and nodule clearance: 6-month results from the RELIEVE-PN study. Poster presented at: 2026 American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO.

Cao P, Xu W, Jiang S, Zhang L. Dupilumab for the treatment of prurigo nodularis: A systematic review. Front Immunol. 2023 Jan 20;14:1092685. doi: 10.3389/fimmu.2023.1092685. PMID: 36742321; PMCID: PMC9895771.

Articles

Six-month interim real-world data from RELIEVE-PN indicate that adults with prurigo nodularis treated with dupilumab experienced significant improvements in two high-burden domains: pruritus intensity and nodule burden. Participants were recruited through a U.S. patient support program and followed longitudinally via patient-reported surveys at baseline, 1, 3, and 6 months. Improvements were evident as early as 1 month and were maintained through 6 months, including among those remaining on therapy.

In a Q&A from AAD 2026, Elmariah highlights a variety of significant results highlighted in a poser session from the RELIEVE-PN study regarding dupilumab for prurigo nodularis.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

RELIEVE-PN: Prurigo Nodularis Improves Over 6 Months on Dupilumab, With Sarina Elmariah, MD, PhD, MPH

Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.

Each week, we highlight 5 key developments or headlines from healthcare that you need to know—whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week's top stories include the US Food and Drug Administration (FDA) approval of sparsentan (Filspari) for the treatment of 

focal segmental glomerulosclerosis (FSGS)

, positive topline phase 2 data for SPY001 in 

, the FDA acceptance of a supplemental New Drug Application (sNDA) for delgocitinib (Anzupgo) cream for the treatment of moderate-to-severe chronic hand eczema in adolescents aged 12 to 17 years, the discontinuation of Insmed Incorporated’s brensocatib development program in 

, and the tentative FDA approval of a generic semaglutide injection submitted by Apotex Corp.

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here’s your quick dive into the top stories for the week of April 12, 2026—let’s jump in!

FDA Approves Sparsentan for Focal Segmental Glomerulosclerosis

On April 13, 2026, the FDA granted full approval to Travere Therapeutics’ sparsentan (Filspari) for the treatment of FSGS, supported by data from 2 of the largest head-to-head interventional studies in adult and pediatric patients with FSGS, the phase 3 DUPLEX study and the phase 2 DUET study. The decision makes sparsentan the first and only drug approved for this indication.

SPY001, An Anti-α4β7, Shows Promise in Phase 2 SKYLINE Trial for Ulcerative Colitis

On April 13, 2026, Spyre Therapeutics announced positive 12-week induction data from Part A of the phase 2 SKYLINE trial of SPY001, a potential best-in-class anti-α4β7 being investigated for the treatment of moderate-to-severely active UC. The Company additionally announced that recruitment for Part A of SKYLINE is now closed and enrollment is open for Part B, which includes 3 monotherapy cohorts (SPY001, SPY002, and SPY003) and 3 combination cohorts (SPY120, SPY130, and SPY230) into which participants may be randomized versus a shared placebo. Proof-of-concept induction data for the remaining cohorts of Part A are now expected mid-2026 (SPY002) and Q3 2026 (SPY003), while Part B induction data for all cohorts remain on track for 2027.

FDA Accepts Delgocitinib sNDA for Chronic Hand Eczema in Adolescents Aged 12–17

On April 15, 2026, the FDA accepted an sNDA for delgocitinib (Anzupgo) cream for the treatment of moderate-to-severe chronic hand eczema in adolescents aged 12 to 17 years. The filing acceptance marks the first regulatory review pathway in the United States specifically targeting the pediatric age group for chronic hand eczema and comes less than 1 year after delgocitinib cream became the first therapy to receive FDA approval for chronic hand eczema in adults in July 2025.

Brensocatib Phase 2b Study in HS Does Not Meet Endpoints, Program Discontinued

Insmed Incorporated announced that the phase 2b CEDAR study evaluating brensocatib in adult patients with moderate to severe hidradenitis suppurativa did not meet its primary or secondary efficacy endpoints in either the 10 mg or 40 mg treatment arms. Based on these data, Insmed indicated plans to discontinue its development program of brensocatib in this disease state and to present these data at a future congress.

FDA Gives Tentative Approval of ANDA for Generic Semaglutide Injection

The FDA announced its tentative approval of an Abbreviated New Drug Application (ANDA) for a generic semaglutide injection submitted by Apotex Corp. The decision marks a regulatory step toward potential generic competition in the GLP-1 RA class. However, the approval does not permit immediate marketing but indicates that the application meets FDA standards for quality, safety, and efficacy, pending resolution of patent or exclusivity barriers.

FDA actions and readouts this week spanned nephrology, immunology, dermatology, and metabolic therapeutics. Sparsentan received full approval as the first indicated therapy for focal segmental glomerulosclerosis, supported by phase 3 DUPLEX and phase 2 DUET data. Spyre reported positive induction results for SPY001 in moderate-to-severe ulcerative colitis and moved into monotherapy and combination cohorts. FDA accepted an adolescent sNDA for topical delgocitinib in chronic hand eczema, while Insmed halted brensocatib in hidradenitis suppurativa after a negative phase 2b CEDAR study. Apotex received tentative ANDA approval for generic semaglutide.

Stay updated with the latest healthcare breakthroughs, including FDA actions and new topline clinical trial data, in this week’s essential news roundup.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

The HCPFive: Top News for Healthcare Providers from the Week of 04/12

Reducing COPD Exacerbations With Tozorakimab, With Frank Sciurba, MD

Tozorakimab, an investigational monoclonal antibody targeting the IL-33 pathway has demonstrated statistically significant and clinically meaningful reductions in 

 (COPD) exacerbations in 2 phase 3 trials, with benefit extending across all blood eosinophil counts and all stages of lung function severity, according to an announcement by AstraZeneca on the phase 3 OBERON and TITANIA trials.

spoke with investigator Frank C. Sciurba, MD, about the new findings, who argued that tozorakimab could open a new therapeutic avenue for the majority of COPD patients who remain inadequately served by current biologic options.

Sciurba, tenured professor of medicine and director of the Emphysema COPD Research Center at the University of Pittsburgh School of Medicine, serves as chief investigator of the LUNA program evaluating tozorakimab (AstraZeneca) in COPD.

Both TITANIA and OBERON were randomized, double-blind, placebo-controlled trials with a combined enrollment of 2,306 patients, recruited irrespective of blood eosinophil count, smoking status, or lung function severity stage, all of whom received tozorakimab 300 mg subcutaneously once every 4 weeks or placebo for 52 weeks on top of standard-of-care inhaled maintenance therapy. The primary endpoint in both trials was the annualized rate of moderate-to-severe COPD exacerbations in the primary population of former smokers; key secondary endpoints assessed the overall population of former and current smokers combined. Both studies met their primary and key secondary endpoints, with tozorakimab demonstrating a statistically significant reduction in moderate-to-severe exacerbations versus placebo in the primary population and in the broader overall population. The safety profile was described as generally favorable and consistent with prior tozorakimab experience. Full results will be presented at a forthcoming scientific meeting; no specific effect-size data have yet been disclosed.

Sciurba described tozorakimab's mechanism as mechanistically upstream of every currently approved biologic in COPD. IL-33 is released by the airway epithelium in response to a variety of stimuli — microbial, irritant, and allergic — and upon release, it engages both innate and adaptive immune responses, feeding into the Th2-mediated pathway that drives eosinophilic inflammation as well as the Th1 and Th17 pathways associated with neutrophilic inflammation. Tozorakimab uniquely inhibits both the reduced and oxidised forms of IL-33, potentially disrupting not only the inflammatory cascade but also the cycle of mucus dysfunction that contributes to disease progression in COPD. This positioning upstream of existing therapeutic targets means the drug theoretically modulates pathways that IL-4 receptor antagonists such as dupilumab and IL-5 inhibitors do not reach — in particular the Th1-dominant inflammatory environment that characterizes most COPD patients.

That distinction has direct clinical implications. The currently approved biologics for COPD — dupilumab, which targets the IL-4 receptor α chain and thus blocks IL-4 and IL-13 signaling, and IL-5 inhibitors — are mechanistically specific to the Th2 pathway and are most effective in patients with elevated blood eosinophil counts. Sciurba estimated that Th2-predominant patients represent approximately 30% of the overall COPD population, leaving the majority — those with low eosinophil counts and a Th1- or Th17-dominant inflammatory phenotype — without a targeted biologic option. This group tends to respond poorly to inhaled corticosteroids and, data suggest, may also derive less benefit from systemic steroids during exacerbations. The OBERON and TITANIA finding that tozorakimab reduced exacerbations across all blood eosinophil counts therefore carries particular significance: it raises the possibility that IL-33 blockade may provide benefit regardless of the dominant inflammatory subtype, addressing a population for which no comparable agent currently exists.

Sciurba noted a pharmacological nuance in this context: the Th1 pathway, while contributing to pathological inflammation in COPD when excessively activated, also serves important homeostatic functions in antimicrobial defense, antiviral immunity, and cancer surveillance. Therapeutic strategies that broadly suppress Th1 responses therefore carry theoretical risks that pathway-specific targeting approaches must carefully calibrate. The OBERON and TITANIA safety data, described as favorable, will be scrutinized in this context when full results are disclosed. Additional trials under the LUNA program — including PROSPERO, a long-term extension study enrolling completers from OBERON and TITANIA, and MIRANDA, assessing an alternative dosing regimen — are ongoing, with data expected in the first half of 2026.

“Tozarakimab is a monoclonal against the IL-33 ligand, and it's involved in a lot of the inflammatory pathways that are affected in COPD. It interestingly affects both Th2 pathways as well as Th1 pathways, and that is of great interest in COPD,” Sciurba said.

Sciurba has reported disclosures including AstraZeneca, COPD Foundation, Gala Therapeutics, GlaxoSmithKline, National Institute of Health, Nuvaira, Patient-Centered Outcomes Research Institute, Pulmonx Corporation, Sano, U.S. Department of Defense, University of Pittsburgh, and Verona Pharma.

AstraZeneca. Tozorakimab met primary endpoint in both OBERON and TITANIA phase III trials in patients with COPD. Press release. March 27, 2026. Accessed March 27, 2026. 

https://www.businesswire.com/news/home/20260327464200/en/Tozorakimab-met-primary-endpoint-in-both-OBERON-and-TITANIA-Phase-III-trials-in-patients-with-COPD

Videos

Tozorakimab significantly reduced moderate-to-severe exacerbations in COPD regardless of blood eosinophil count.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

What's New in Atopic Dermatitis Management, With April Armstrong, MD, MPH

The atopic dermatitis treatment landscape is evolving at an unprecedented pace, according to April W. Armstrong, MD, MPH, of UCLA's David Geffen School of Medicine, and those working in the field are working to keep up.

2026 American Academy of Dermatology (AAD) Annual Meeting

 in Denver, Colorado, Armstrong spoke about various key developments spanning long-term safety data, emerging mechanisms of action, and the increasing role of personalized treatment strategies in the moderate-to-severe atopic dermatitis space.

“Some of the things that I highlighted in my session included long-term data for the FDA-approved therapies, both in the biologic realm as well as oral JAK inhibitors,” Armstrong expressed.

On the topic of safety data, Armstrong provided reassurance related to oral Janus kinase (JAK) inhibitors. She noted long-term findings show rates of serious infections and major adverse cardiovascular events (MACE) in the atopic dermatitis population appear to be comparable to background rates seen in patients with moderate-to-severe disease. With this in mind, Armstrong stressed the value of Zoster vaccination prior to, or concurrent with, beginning oral JAK inhibitor treatment, given the link to elevated risk of Zoster infection.

Later in the interview, Armstrong turned her attention to the drug pipeline, touching on the wave of innovations seen across both familiar and novel therapeutic pathways. Longer-term data were noted as currently available for agents targeting the OX40 ligand pathway. Newer approaches are also exploring more precise inhibition of the interleukin (IL)-4 receptor alpha.

Outside of biologics, Armstrong also spoke about oral drugs targeting STAT6, as opposed to JAK molecules, emerging as noteworthy in dermatology. She also pointed to the growing interest in bi-specific and tri-specific molecules designed to simultaneously inhibit multiple targets, an approach aimed at addressing the heterogeneity of disease presentations.

Despite the momentum, Armstrong later described the management of moderate-to-severe atopic dermatitis as continuing to be a highly individualized challenge. For individuals with refractory disease, she encouraged clinicians in the field not to be discouraged, emphasizing combination therapy as potentially appropriate for certain patients.

The quotes used in this video summary were edited for clarity.

Armstrong has served as a consultant for and received honoraria from AbbVie, Almirall, Arcutis, ASLAN, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Dermira, EPI, Incyte, Janssen, LEO Pharma, Eli Lilly, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun, and UCB and has participated in advisory boards for Boehringer Ingelheim and Parexel.

Armstrong A, et al. S065 What's New in Dermatology. Session presented at: 2026 American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO.

Armstrong AW, Rubin C, Jarell A, et al. Real-world effectiveness of 12 months tralokinumab treatment in patients with skin of color and moderate-to-severe atopic dermatitis: final data from the prospective, non-interventional, international TRACE study. Presented at the 2026 American Academy of Dermatology Annual Meeting; March 27-31, 2026; Denver, CO. Poster ID: 77199. Oral Poster Presentation.

At AAD, April W. Armstrong, MD, MPH, discussed recent innovations in the atopic dermatitis treatment space, highlighting long-term safety data and more.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

Kimberly Brown, MD, is division chief of gastroenterology and hepatology and the Associate Medical Director of the Henry Ford Hospital Transplant Institute at Henry Ford Hospital. She is also a Professor of Medicine at Wayne State University

Meena Bansal, MD, is director of the MASLD/MASH (NAFLD/NASH) Center of Excellence at Mount Sinai and System Chief, Division of Liver Diseases for the Mount Sinai Health System.

PCOS, Pregnancy, and MASLD Risk: What Clinicians Need to Know

metabolic dysfunction-associated steatotic liver disease (MASLD)

 continues to grow, increasing attention is being paid to how reproductive and metabolic conditions uniquely shape risk in women. Among these, 

 and pregnancy represent critical but often underrecognized periods where hormonal and metabolic factors intersect to influence liver health.

In this segment from a recent episode of 

Liver Lineup: Updates and Unfiltered Insights

, Meena Bansal, MD, joins hosts Nancy Reau, MD, and Kimberly Brown, MD, to examine the complex relationship between PCOS, pregnancy, and MASLD.

Bansal emphasizes that PCOS is a well-established risk factor for MASLD and its more advanced form, MASH, largely driven by underlying insulin resistance. While the condition is widely recognized in endocrinology, its implications for liver health are often underappreciated. She notes that patients with PCOS should be evaluated for liver fibrosis using noninvasive tools, and those with evidence of stage 2 or 3 fibrosis may be appropriate candidates for currently approved therapies.

The discussion then shifts to pregnancy as a critical period of risk. Women entering pregnancy with metabolic comorbidities such as obesity or diabetes may already be predisposed to MASLD, and the physiologic changes of pregnancy, including weight gain, can further exacerbate disease progression. According to Bansal, emerging data suggest that MASLD during pregnancy is associated with increased risks of adverse maternal outcomes, including gestational diabetes and preeclampsia, as well as complications for the fetus, such as preterm birth and abnormal growth patterns.

The conversation also touches on the potential for long-term, intergenerational effects. Bansal highlights research suggesting that maternal metabolic health may influence fetal outcomes through epigenetic mechanisms, potentially increasing a child’s lifetime risk of metabolic disease and liver dysfunction. While she says these findings require further validation, they underscore the broader implications of MASLD beyond the individual patient.

Reau and Brown further explore how current therapies fit into this landscape, particularly for younger, premenopausal women. Although GLP-1 receptor agonists have shown benefits in weight loss and metabolic regulation and may even improve menstrual regularity in some patients with PCOS, their use is contraindicated during pregnancy. Bansal points out the challenges this creates in preconception care, including uncertainty around weight regain after discontinuation and its potential impact during pregnancy.

As Bansal notes, more research is needed to better understand how to tailor care for women with MASLD, especially during periods of hormonal and metabolic transition.

Editors’ note: Relevant disclosures for 

 include AbbVie, Gilead, Salix, Arbutus, and VIR. Relevant disclosures for 

 include Mallinckrodt Pharmaceuticals, Gilead, Salix, Intercept, Ipsen, and Madrigal. Relevant disclosures for 

 include Boeheringer-Ingelheim, Boston Pharma, Fibronostics, GSK, Madrigal, Merck, NOVO Nordisk, and The Kinetix Group.

DiStefano JK. NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment. Endocrinology. 2020;161(10):bqaa134. doi:10.1210/endocr/bqaa134

Sarkar M, Kushner T. Metabolic dysfunction-associated steatotic liver disease and pregnancy. J Clin Invest. 2025;135(10):e186426. Published 2025 May 15. doi:10.1172/JCI186426

Mass General Brigham. Patients Who Discontinued GLP-1s Had More Weight Gain, Complications During Pregnancy. November 24, 2025. Accessed April 17, 2026. 

https://www.massgeneralbrigham.org/en/about/newsroom/press-releases/pregnancy-effects-from-discontinued-glp-1-use

Experts discuss how metabolic and hormonal factors in women influence MASLD risk, progression, and potential long-term outcomes.

Hepatology

Polycystic Ovary Syndrome

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

MASLD and Women’s Health: The Roles of PCOS and Pregnancy

Roy Beck, MD, PhD, is the founder of the Jaeb Center for Health Research.

Beck discusses a recent analysis of the phase 4 trial comparing TI and degludec against standard treatment, highlighting the need for individualized titration.

Type 1 Diabetes

INHALE-3 Analysis Supports Need for Increased Technosphere Insulin Doses, With Roy Beck, MD, PhD

Marie-José van Tol, PhD, from the University of Groningen.

Research suggests preventive cognitive therapy reduced relapse risk in recurrent depression by improving positive affect and anhedonia, van Tol explained in an interview.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Preventive Therapy Targeting Positive Affect May Reduce MDD Relapse, With Marie-José van Tol, PhD

Hanna describes the "freedom" patients with sickle cell disease reported after being treated with reni-cel, a one-time edited gene therapy. 

Hematology

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

Strategic Alliance Partnership

One-Time Gene-Editing Therapy Gives Patients “Freedom” From Pain Crisis

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

View slated expert interviews and 7 clinical trials to watch at AACE Annual Meeting 2026.

AACE Annual Meeting 2026 Preview: 7 Trials to Know

Silvia Mariel Ferrucci, MD, is an adjunct professor of dermatology at the University of Milan and the head of the the Allergology Dermatology Service at Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico.

In this Q&A interview, Ferrucci highlights key real-world findings from the GLOBOSTAD on the safety and efficacy of dupilumab (Dupixent) in atopic dermatitis.

GLOBOSTAD: 3 Year Efficacy of Dupilumab in Atopic Dermatitis, With Silvia Mariel Ferrucci, MD

Phillip Levy is an Assistant Professor of Emergency Medicine and Assistant Professor of Physiology at Wayne State University and the Assistant Vice President for Research at Wayne State University Department of Emergency Medicine.

Data from a study deploying mobile health units across Detroit, Michigan, found CKD stage ≥3 rates double the national average and increased rates in at-risk subgroups.


Chronic Kidney Disease

This City’s CKD Stage ≥ 3 Incidence is Double The US National Average

Blauvelt discusses studies revealing that disease severity, injection frequency, pain, and geography all shape treatment preferences.



Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Understanding Patient Preferences in Psoriasis, With Andrew Blauvelt, MD, MBA

Armstrong highlights several major takeaways from her portion of the AAD 2026 session titled 'IL-23 Innovation: New Data Addressing Plaque Psoriasis.'

Highlighting Key IL-23 Innovations in Dermatology, With April W. Armstrong, MD, MPH

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Podcasts

This episode explores the launch and accessibility of FDA-approved oral GLP-1 orforglipron, including availability through Amazon Pharmacy's same-day delivery service.

FDA News

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue: Orforglipron Availability, Amazon Pharmacy, and Dosing Considerations

Vaiibhav Patel, MD, is a cardiologist at the Ohio State University Wexner Medical Center.

Patel provides an inside perspective on one of the most diagnostically challenging cardiovascular conditions.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Latest News

RELIEVE-PN: Prurigo Nodularis Improves Over 6 Months on Dupilumab, With Sarina Elmariah, MD, PhD, MPH

The HCPFive: Top News for Healthcare Providers from the Week of 04/12

Reducing COPD Exacerbations With Tozorakimab, With Frank Sciurba, MD

What's New in Atopic Dermatitis Management, With April Armstrong, MD, MPH

MASLD and Women’s Health: The Roles of PCOS and Pregnancy